Hi Tech Pharmacal (Nasdaq: HITK) reported earnings on Sep. 5. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended July 31 (Q1), Hi Tech Pharmacal missed estimates on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped significantly.

Margins shrank across the board.

Revenue details
 Hi Tech Pharmacal chalked up revenue of $52.0 million. The four analysts polled by S&P Capital IQ anticipated revenue of $57.6 million on the same basis. GAAP reported sales were 7.4% lower than the prior-year quarter's $56.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.44. The four earnings estimates compiled by S&P Capital IQ predicted $0.68 per share. GAAP EPS of $0.44 for Q1 were 58% lower than the prior-year quarter's $1.05 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 48.7%, 1,040 basis points worse than the prior-year quarter. Operating margin was 16.3%, 1,980 basis points worse than the prior-year quarter. Net margin was 11.5%, 1,300 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $57.1 million. On the bottom line, the average EPS estimate is $0.59.

Next year's average estimate for revenue is $238.1 million. The average EPS estimate is $2.64.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 205 members out of 223 rating the stock outperform, and 18 members rating it underperform. Among 52 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 45 give Hi Tech Pharmacal a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $37.83.